FDA approves generic versions of Merck's Zocor
Article Abstract:
A generic form of the cholesterol reducing drug Zocor has been approved for sale by the United States Food and Drug Administration. The generic pharmaceutical was developed by Teva Pharmaceuticals Industries Ltd. of Israel and Ranbaxy Pharmaceuticals Inc. of the United States. The price of the generic drug will be approximately 30 percent less than the brand name Zocor which generated $4.4 billion for Merck & Company Inc. of the United States last year.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Abbott suspends late-stage trial of cancer drug
Article Abstract:
Abbott Laboratories has halted the clinical trial of its atasentan cancer drug in its late stages. The drug was designed to prevent tumor growth, although it was not expected to eliminate them.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Novartis to sell Prilosec copy in U.S
Article Abstract:
Novartis AG will introduce a version of AstraZeneca PLC's Prilosec cancer drug in the U.S. Novartis is the third company to launch a version of the Prilosec drug.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: MMC to investigate lenders' snubbing of architects' mortgage valuation work. The art of commerce: Michael Squire is a successful commercial architect whose dedication belies narrow assumptions about his field
- Abstracts: You first: Japan's big car makers remain wary of China. Be sure to bring money
- Abstracts: Banyu holders pressure Merck to increase offer. Merck KGaA seeks to restore stature with bid. Banyu shareholders are wary of Merck bid
- Abstracts: Russian energy deal offers foreigners access to giant: Putin backs plan to boost state control of Gazprom, lift limits on ownership
- Abstracts: Philips net income fell 28% in quarter. Aegon's quarterly profit slid 36%. Philips posts big loss on investment charges